Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The case for prostate cancer screening

G L Andriole1

  • 1Department of Surgery, Washington University School of Medicine, St Louis, MO 63110.

Seminars in Urology
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia.

BMC urology·2021
Same author

Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.

Urology·2019
Same author

The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens.

Scandinavian journal of urology·2019
Same author

The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens.

Prostate cancer and prostatic diseases·2017
Same author

Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE.

Prostate cancer and prostatic diseases·2016
Same author

Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study.

Prostate cancer and prostatic diseases·2016
Same journal

The molecular staging of prostate cancer.

Seminars in urology·1995
Same journal

New treatment strategies for hormone refractory prostate cancer.

Seminars in urology·1995
Same journal

Cryosurgical ablation for prostate cancer: a current review.

Seminars in urology·1995
Same journal

Role of induction androgen deprivation before radical prostatectomy.

Seminars in urology·1995
Same journal

Reducing length of stay after radical prostatectomy.

Seminars in urology·1995
Same journal

Early intervention or expectant management for prostate cancer. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer.

Seminars in urology·1995
See all related articles

Prostate cancer screening is increasingly seen as appropriate. Further research is needed to determine optimal screening ages and the role of PSA testing in reducing cancer mortality.

Area of Science:

  • Urology
  • Oncology
  • Preventive Medicine

Background:

  • Growing evidence suggests prostate cancer screening is rational.
  • Optimal screening protocols and the precise role of biomarkers require further definition.

Purpose of the Study:

  • To define optimal ages for prostate cancer screening.
  • To determine the role of PSA, PSA velocity, and PSA density in serial screening.
  • To justify screening through demonstration of reduced cancer morbidity and mortality.

Main Methods:

  • A prospective, randomized trial is planned to evaluate prostate cancer screening effectiveness.
  • Analysis will focus on morbidity and mortality reduction attributable to screening.

Main Results:

Related Experiment Videos

  • Evidence is mounting for the appropriateness of prostate cancer screening.
  • Optimal screening ages and biomarker roles require further investigation.

Conclusions:

  • Prostate cancer screening is considered rational and appropriate.
  • Further research, including a prospective randomized trial, is essential to confirm benefits and refine screening strategies.